- Home
- SJT vs MOLN Comparison
SJT vs MOLN Comparison
Compare SJT & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | SJT | MOLN |
|---|---|---|
| Founded | 1980 | 2004 |
| Country | United States | Switzerland |
| Employees | 495 | N/A |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 257.7M | 158.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SJT | MOLN |
|---|---|---|
| Price | $5.02 | $5.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.38 |
| AVG Volume (30 Days) | ★ 231.8K | 1.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $285.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.55 | $3.36 |
| 52 Week High | $7.22 | $5.36 |
Technical Indicators
Market Signals| Indicator | SJT | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 34.92 | 48.82 |
| Support Level | N/A | $3.50 |
| Resistance Level | $5.95 | $4.80 |
| Average True Range (ATR) | 0.20 | 0.18 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 16.39 | 10.96 |
Price Performance
Historical ComparisonAbout SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.